Morgan Stanley initiates Csquare stock with overweight rating on retail colocation exposure

Morgan Stanley initiated coverage on Csquare (CSQR) with an overweight rating and a $26.00 price target, implying ~20% upside from ~$21.52. The company reported Q2’26 revenue up 14.5% YoY to $280.4M and adjusted EBITDA up 21% to $120.3M, with record bookings of $64.7M (13th straight quarter of sequential growth); over 60% of bookings were AI-related and ~95% of revenue is recurring. The note also highlights a heavy ~$5.76B debt load, but IPO proceeds are expected to reduce annual interest expense by ~$63M and enable deleveraging from ~9x (3Q26) toward ~6–7x by end-2028.

Analysis

The market is likely pricing this as a leverage-shaped growth story, not a pure fundamentals story. That matters: when a company is still running high debt, incremental EBITDA has an outsized effect on equity value, so the stock can rerate faster than peers if execution holds — but it can also de-rate violently if growth slips or financing costs reprice. The key second-order effect is that equity holders are effectively buying a long-duration option on capacity conversion; the balance sheet is the real source of convexity, not just revenue growth.

Relative to the large-cap colo complex, the opportunity is not that CSQR becomes EQIX; it is that the market may temporarily pay up for scarcer AI-adjacent capacity on a cheaper starting multiple. That can pressure smaller private operators and levered listed peers that lack runway or capital access, because customers will gravitate toward proven power delivery and balance-sheet certainty. The valuation gap versus EQIX may narrow if bookings convert cleanly, but only if interconnection growth compounds fast enough to offset the leverage discount.

The main risk is that AI-linked bookings are front-end loaded and noisy: they often precede revenue by quarters and can overstate durable demand if deployment schedules slip or customers delay turn-up. Over the next 1-3 months, the catalyst path is continued execution and any commentary on power availability, capex intensity, and contract conversion; over 6-18 months, the thesis lives or dies on deleveraging toward the 6-7x range. The contrarian view is that the stock already reflects a decent amount of good news, and the current discount to EQIX is partly justified by scale, financing, and quality gaps rather than a mispricing.

Key Decisions for Investors

• Initiate a small long CSQR position only on weakness in the next 1-2 weeks; treat it as a 3-6 month execution trade with upside toward the low-$20s/upper-$20s if growth and deleveraging stay on track, but cut if management reiterates leverage without showing booked-to-bill conversion.
• For higher-conviction exposure, use CSQR call spreads instead of common stock over the next 1-3 months; this caps downside if the multiple rerates less than expected while preserving upside into the next quarterly update.
• Relative value: long CSQR / short EQIX as a tactical pair only if the market starts rewarding faster growth over quality; stop the pair if CSQR fails to show continued booking conversion or if EQIX outperforms on risk-off flows.
• Watch the credit market closely: if CSQR secondary debt spreads widen meaningfully or refinancing chatter reappears before deleveraging progress, the equity thesis weakens fast; that would be the cleanest falsifier within 1-2 quarters.
• If already long, take some profit into strength above the initiation-driven move and keep a core only for evidence of sustained capacity additions and margin stability through the next two earnings prints.